Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
Date:2/7/2013

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
  • Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012.
  • "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin , president and CEO of Avanir.  "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications."

    Fiscal 2013 First Quarter Results

  • Total net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012.
  • Cash used in operations was $12.7
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
    (Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
    (Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
    Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
    ... that results from the REMEDEE study ( R andomized ... inal sirolimus coat ED bio- E ... Therapy Stent is non-inferior to the TAXUS® Liberte® paclitaxel-eluting stent, with ... results were presented by Michael Haude, M.D., director of Medical Clinic ...
    ... University Hospitals (UH) Case Medical Center, Case Western ... today the initiation of a novel Phase I clinical ... hematopoietic stem cells (HSCs) from the dose limiting toxicity ... Americans are diagnosed with glioblastoma every year and only ...
    Cached Medicine Technology:REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 2REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 3REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 4Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
    (Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
    (Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
    (Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... one in five patients operated on for broken bones or ... a new study finds. Less-educated patients and patients ... likely to be "doctor shoppers," said study lead author Dr. ... Overall, he said, the study suggests that doctors aren,t talking ...
    (Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
    (Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
    Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
    ... simple sugar is in fact a critical regulator of ... when disturbed, this process could contribute to cancer or ... and timing of cell division, the researchers say. , ... used inside cells to modify proteins, turning the proteins ...
    ... range of user-controlled products that would help women protect ... be developed in any form that is convenient to ... ,These microbicides will enable women to negotiate ... at risk and would also help avoid unwanted pregnancies, ...
    ... a rare, benign intra-articular lesion of unknown aetiology. //It ... synovium, and forms part of the differential diagnosis for ... 50 cases of Lipoma arborescens have previously been reported, ... of other joints including the hip, shoulder, wrist and ...
    ... continues to grow and currently affects more that ... emphasize a need for alternative diabetes therapies with ... ,The delivery of insulin by the lung may ... diabetes. However, alternative insulin delivery systems must meet ...
    ... successful completion of Phase II clinical trials of a novel ... suppressing the immune system has been announced by Researchers at ... chronic, painful disease affecting millions worldwide. It is thrice more ... age. It strikes joints on both sides of the body, ...
    ... to hold on to technological advancements belived to revolutionise ... of computers to improve the quality and effectiveness of ... has now been proved with authencity that even pateints ... successfully educated about health topics using computers that can ...
    Cached Medicine News:Health News:Sugar Helps Control Cell Division 2Health News:Lipoma Arborescens: A Rare Tumor Of The Knee 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Novel drug holds promise for treatment of Rheumatoid Arthritis 2Health News:Computers Can Teach Patients About Screening for Cancer 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
    Medicine Products: